Prognostic value of mutational characteristics in gastrointestinal stromal tumors: A single-center experience in 275 cases

Medical Oncology

Volumn 31, Issue 1, 2014, Pages

  Wang, Ming ^a   Xu, Jia ^a   Zhao, Wenyi ^a   Tu, Lin ^a   Qiu, Weiqing ^a   Wang, Chaojie ^a   Shen, Yangyin ^a   Liu, Qiang ^a   Cao, Hui ^a  

^a SHANGHAI JIAO TONG UNIVERSITY   (China)

Author keywords

Gastrointestinal stromal tumors; KIT; Mutation; PDGFRA; Survival

Indexed keywords

IMATINIB; CODON;

ADULT; AGED; ARTICLE; CANCER GRADING; CANCER PROGNOSIS; CANCER RECURRENCE; CANCER SURGERY; CODON; EXON; FEMALE; GASTROINTESTINAL STROMAL TUMOR; GENE; GENE DELETION; GENE MUTATION; GENOTYPE; HUMAN; KIT GENE; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; MITOSIS RATE; MUTATIONAL ANALYSIS; NUCLEOTIDE SEQUENCE; PDGFRA GENE; PRIORITY JOURNAL; RECURRENCE FREE SURVIVAL; TUMOR LOCALIZATION; TUMOR VOLUME; VERY ELDERLY; COHORT ANALYSIS; DISEASE FREE SURVIVAL; DNA MUTATIONAL ANALYSIS; FOLLOW UP; GASTROINTESTINAL STROMAL TUMORS; GENETICS; MITOSIS; PROGNOSIS; RECURRENT DISEASE; RISK; STOMACH NEOPLASMS; TUMOR RECURRENCE;

ADULT; AGED; AGED, 80 AND OVER; CODON; COHORT STUDIES; DISEASE-FREE SURVIVAL; DNA MUTATIONAL ANALYSIS; FEMALE; FOLLOW-UP STUDIES; GASTROINTESTINAL STROMAL TUMORS; GENOTYPE; HUMANS; MALE; MIDDLE AGED; MITOSIS; NEOPLASM RECURRENCE, LOCAL; PROGNOSIS; RECURRENCE; RISK; STOMACH NEOPLASMS;

MLCS; MLOWN;

EID: 84889961197     PISSN: 13570560     EISSN: 1559131X     Source Type: Journal    
DOI: 10.1007/s12032-013-0819-x     Document Type: Article

References (40)

1. ESMO/European Sarcoma Network Working Group. Gastrointestinal stromal tumors: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2012;23(Suppl 7):vii49-55. doi: 10.1093/annonc/mds252.
2. Paral J, Slaninka I, Kalabova H, Hadzi-Nikolov D. Gastrointestinal stromal tumors: review on morphology, molecular pathology, diagnostics, prognosis and treatment options. Acta Gastro-Enterologica Belgica. 2010;73(3):349-59.
3. Corless CL, Barnett CM, Heinrich MC. Gastrointestinal stromal tumours: origin and molecular oncology. Nat Rev Cancer. 2011;11(12):865-78. doi: 10.1038/nrc3143.
4. Joensuu H, Eriksson M, Hall KS, Hartmann JT, Pink D, Schutte J, et al. One vs three years of adjuvant imatinib for operable gastrointestinal stromal tumor a randomized trial. JAMA. 2012;307(12):1265-72.
5. Delahaye NF, Rusakiewicz S, Martins I, Menard C, Roux S, Lyonnet L, et al. Alternatively spliced NKp30 isoforms affect the prognosis of gastrointestinal stromal tumors. Nat Med. 2011;17(6):700. doi: 10.1038/nm.2366.
6. Joensuu H, Vehtari A, Riihimaki J, Nishida T, Steigen SE, Brabec P, et al. Risk of recurrence of gastrointestinal stromal tumour after surgery: an analysis of pooled population-based cohorts. Lancet Oncol. 2012;13(3):265-74. doi: 10.1016/S1470-2045(11)70299-6.
7. Rubin BP, Heinrich MC, Corless CL. Gastrointestinal stromal tumour. Lancet. 2007;369(9574):1731-41. doi: 10.1016/S0140-6736(07)60780-6. (Pubitemid 46778870)
8. Demetri GD, van Oosterom AT, Garrett CR, Blackstein ME, Shah MH, Verweij J, et al. Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial. Lancet. 2006;368(9544):1329-38. doi: 10.1016/s0140-6736(06) 69446-4. (Pubitemid 44528723)
9. Eisenberg BL, Harris J, Blanke CD, Demetri GD, Heinrich MC, Watson JC, et al. Phase II trial of neoadjuvant/adjuvant imatinib mesylate (IM) for advanced primary and metastatic/recurrent operable gastrointestinal stromal tumor (GIST): early results of RTOG 0132/ACRIN 6665. J Surg Oncol. 2009;99(1):42-7. doi: 10.1002/jso.21160.
10. Joensuu H. Risk stratification of patients diagnosed with gastrointestinal stromal tumor. Hum Pathol. 2008;39(10):1411-9. doi: 10.1016/j.humpath.2008.06.025.
11. Demetri GD, von Mehren M, Antonescu CR, DeMatteo RP, Ganjoo KN, Maki RG, et al. NCCN task force report: update on the management of patients with gastrointestinal stromal tumors. J Natl Compr Cancer Netw. 2010;8:S1-43.
12. Dematteo RP, Gold JS, Saran L, Gonen M, Liau KH, Maki RG, et al. Tumor mitotic rate, size, and location independently predict recurrence after resection of primary gastrointestinal stromal tumor (GIST). Cancer. 2008;112(3):608-15. doi: 10.1002/cncr.23199. (Pubitemid 351186201)
13. Cerski MR, Pereira F, Matte US, Oliveira FH, Crusius FL, Waengertner LE, et al. Exon 11 mutations, Ki67, and p16(INK4A) as predictors of prognosis in patients with GIST. Pathol Res Pract. 2011;207(11):701-6. doi: 10.1016/j.prp.2011.09.008.
14. Arne G, Kristiansson E, Nerman O, Kindblom LG, Ahlman H, Nilsson B, et al. Expression profiling of GIST: CD133 is associated with KIT exon 11 mutations, gastric location and poor prognosis. Int J Cancer. 2011;129(5):1149-61. doi: 10.1002/ijc.25755.
15. Bachet JB, Landi B, Laurent-Puig P, Italiano A, Le Cesne A, Levy P, et al. Diagnosis, prognosis and treatment of patients with gastrointestinal stromal tumour (GIST) and germline mutation of KIT exon 13. Eur J Cancer. 2013;. doi: 10.1016/j.ejca.2013.04.005.
16. Lv A, Li Z, Tian X, Guan X, Zhao M, Dong B, et al. SKP2 high expression, KIT exon 11 deletions, and gastrointestinal bleeding as predictors of poor prognosis in primary gastrointestinal stromal tumors. PLoS ONE. 2013;8(5):e62951. doi: 10.1371/journal.pone.0062951.
17. Parkin B, Chugh R. Molecular pathology of gastrointestinal stromal tumors and implications for treatment and prognosis. Curr Probl Cancer. 2011;35(5):245-54. doi: 10.1016/j.currproblcancer.2011.10.002.
18. Roskoski R Jr. Structure and regulation of Kit protein-tyrosine kinase - the stem cell factor receptor. Biochem Biophys Res Commun. 2005;338(3):1307-15. doi: 10.1016/j.bbrc.2005.09.150. (Pubitemid 41608395)
19. Bachet JB, Hostein I, Le Cesne A, Brahimi S, Beauchet A, Tabone-Eglinger S, et al. Prognosis and predictive value of KIT exon 11 deletion in GISTs. Br J Cancer. 2009;101(1):7-11. doi: 10.1038/sj.bjc.6605117.
20. Fletcher CD, Berman JJ, Corless C, Gorstein F, Lasota J, Longley BJ, et al. Diagnosis of gastrointestinal stromal tumors: a consensus approach. Hum pathol. 2002;33(5):459-65. (Pubitemid 34747864)
21. Demetri GD, Benjamin RS, Blanke CD, Blay JY, Casali P, Choi H, et al. NCCN Task Force report: management of patients with gastrointestinal stromal tumor (GIST)-update of the NCCN clinical practice guidelines. J Natl Compr Cancer Netw. 2007;5(Suppl 2):S1-29 quiz S30.
22. Minarik G, Plank L, Lasabova Z, Szemes T, Burjanivova T, Szepe P, et al. Spectrum of mutations in gastrointestinal stromal tumor patients: a population-based study from Slovakia. APMIS. 2013;121(6):539-48. doi: 10.1111/apm.12019.
23. Wozniak A, Rutkowski P, Piskorz A, Ciwoniuk M, Osuch C, Bylina E, et al. Prognostic value of KIT/PDGFRA mutations in gastrointestinal stromal tumours (GIST): Polish Clinical GIST registry experience. Ann Oncol. 2012;23(2):353-60. doi: 10.1093/annonc/mdr127.
24. Origone P, Gargiulo S, Mastracci L, Ballestrero A, Battistuzzi L, Casella C, et al. Molecular characterization of an Italian series of sporadic GISTs. Gastric Cancer. 2013;16(4):596-601. doi: 10.1007/s10120-012-0213-y.
25. Baker G, Babb C, Schnugh D, Nayler S, Louw M, Goedhals J, et al. Molecular characterisation of gastrointestinal stromal tumours in a South African population. Oncol lett. 2013;5(1):155-60. doi: 10.3892/ol 2012.1013.
26. Braggio E, Braggio Dde A, Small IA, Lopes LF, Valadao M, Gouveia ME, et al. Prognostic relevance of KIT and PDGFRA mutations in gastrointestinal stromal tumors. Anticancer Res. 2010;30(6):2407-14.
27. Corless CL, Fletcher JA, Heinrich MC. Biology of gastrointestinal stromal tumors. J Clin Oncol. 2004;22(18):3813-25. doi: 10.1200/JCO.2004.05.140. (Pubitemid 41095223)
28. Laurini JA, Carter JE. Gastrointestinal stromal tumors: a review of the literature. Arch Pathol Lab Med. 2010;134(1):134-41. doi: 10.1043/2008-0083- RSR2.1.
29. Emile JF, Theou N, Tabone S, Cortez A, Terrier P, Chaumette MT, et al. Clinicopathologic, phenotypic, and genotypic characteristics of gastrointestinal mesenchymal tumors. Clin Gastroenterol Hepatol. 2004;2(7):597-605. (Pubitemid 38834044)
30. Kim TW, Lee H, Kang YK, Choe MS, Ryu MH, Chang HM, et al. Prognostic significance of c-kit mutation in localized gastrointestinal stromal tumors. Clin Cancer Res. 2004;10(9):3076-81. (Pubitemid 38619686)
31. Hou YY, Grabellus F, Weber F, Zhou Y, Tan YS, Li J, et al. Impact of KIT and PDGFRA gene mutations on prognosis of patients with gastrointestinal stromal tumors after complete primary tumor resection. J Gastrointes Surg. 2009;13(9):1583-92. doi: 10.1007/s11605-009-0842-6.
32. Andersson J, Bumming P, Meis-Kindblom JM, Sihto H, Nupponen N, Joensuu H, et al. Gastrointestinal stromal tumors with KIT exon 11 deletions are associated with poor prognosis. Gastroenterology. 2006;130(6):1573-81. doi: 10.1053/j.gastro.2006.01.043. (Pubitemid 43668833)
33. Miettinen M, Sobin LH, Lasota J. Gastrointestinal stromal tumors of the stomach: a clinicopathologic, immunohistochemical, and molecular genetic study of 1765 cases with long-term follow-up. Am J Surg Pathol. 2005;29(1):52-68. (Pubitemid 40023952)
34. Wardelmann E, Losen I, Hans V, Neidt I, Speidel N, Bierhoff E, et al. Deletion of Trp-557 and Lys-558 in the juxtamembrane domain of the c-kit protooncogene is associated with metastatic behavior of gastrointestinal stromal tumors. Int J Cancer. 2003;106(6):887-95. doi: 10.1002/ijc.11323. (Pubitemid 37071667)
35. Martin J, Poveda A, Llombart-Bosch A, Ramos R, Lopez-Guerrero JA, Garcia del Muro J, et al. Deletions affecting codons 557-558 of the c-KIT gene indicate a poor prognosis in patients with completely resected gastrointestinal stromal tumors: a study by the Spanish Group for Sarcoma Research (GEIS). J Clin Oncol. 2005;23(25):6190-8. doi: 10.1200/JCO.2005.19.554.
36. Martin-Broto J, Gutierrez A, Garcia-del-Muro X, Lopez-Guerrero JA, Martinez-Trufero J, de Sande LM, et al. Prognostic time dependence of deletions affecting codons 557 and/or 558 of KIT gene for relapse-free survival (RFS) in localized GIST: a Spanish Group for Sarcoma Research (GEIS) Study. Ann Oncol. 2010;21(7):1552-7. doi: 10.1093/annonc/mdq047.
37. Debiec-Rychter M, Dumez H, Judson I, Wasag B, Verweij J, Brown M, et al. Use of c-KIT/PDGFRA mutational analysis to predict the clinical response to imatinib in patients with advanced gastrointestinal stromal tumours entered on phase I and II studies of the EORTC Soft Tissue and Bone Sarcoma Group. Eur J Cancer. 2004;40(5):689-95. doi: 10.1016/j.ejca.2003.11.025. (Pubitemid 38326618)
38. Debiec-Rychter M, Sciot R, Le Cesne A, Schlemmer M, Hohenberger P, van Oosterom AT, et al. KIT mutations and dose selection for imatinib in patients with advanced gastrointestinal stromal tumours. Eur J Cancer. 2006;42(8):1093-103. doi: 10.1016/j.ejca.2006.01.030. (Pubitemid 44275331)
39. Penzel R, Aulmann S, Moock M, Schwarzbach M, Rieker RJ, Mechtersheimer G. The location of KIT and PDGFRA gene mutations in gastrointestinal stromal tumours is site and phenotype associated. J Clin Pathol. 2005;58(6):634-9. doi: 10.1136/jcp.2004.021766. (Pubitemid 40814026)
40. Emile JF, Tabone-Eglinger S, Theou-Anton N, Lemoine A. Prognostic value of KIT exon 11 deletions in GISTs. Gastroenterology. 2006;131(3):976-7. doi: 10.1053/j.gastro.2006.07.042 author reply 7-8. (Pubitemid 44307094)